
## Aimee N C Campbell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9215363/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Do Treatment Improvements in PTSD Severity Affect Substance Use Outcomes? A Secondary Analysis From a Randomized Clinical Trial in NIDA's Clinical Trials Network. American Journal of Psychiatry, 2010, 167, 95-101.	7.2	268
2	Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders Journal of Consulting and Clinical Psychology, 2009, 77, 607-619.	2.0	258
3	Internet-Delivered Treatment for Substance Abuse: A Multisite Randomized Controlled Trial. American Journal of Psychiatry, 2014, 171, 683-690.	7.2	203
4	ls traumatic stress a vulnerability factor for women with substance use disorders?. Clinical Psychology Review, 2005, 25, 813-823.	11.4	161
5	Using e-technologies in clinical trials. Contemporary Clinical Trials, 2015, 45, 41-54.	1.8	124
6	Developing an opioid use disorder treatment cascade: A review of quality measures. Journal of Substance Abuse Treatment, 2018, 91, 57-68.	2.8	114
7	Effectiveness of HIV/STD Sexual Risk Reduction Groups for Women in Substance Abuse Treatment Programs: Results of NIDA Clinical Trials Network Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 581-589.	2.1	95
8	Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. Addictive Behaviors, 2018, 86, 111-117.	3.0	62
9	The Impact of Trauma-Focused Group Therapy upon HIV Sexual Risk Behaviors in the NIDA Clinical Trials Network "Women and Trauma―Multi-Site Study. AIDS and Behavior, 2010, 14, 421-430.	2.7	56
10	Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: An example from the NIDA Clinical Trials Network. Contemporary Clinical Trials, 2012, 33, 386-395.	1.8	50
11	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug and Alcohol Dependence, 2020, 217, 108335.	3.2	50
12	The role of alcohol misuse in PTSD outcomes for women in community treatment: A secondary analysis of NIDA's Women and Trauma Study. Drug and Alcohol Dependence, 2010, 111, 114-119.	3.2	49
13	No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. Addictive Behaviors, 2017, 71, 104-106.	3.0	49
14	Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial. Drug and Alcohol Dependence, 2016, 161, 119-126.	3.2	45
15	Intimate partner violence outcomes in women with PTSD and substance use: A secondary analysis of NIDA Clinical Trials Network "Women and Trauma―Multi-site Study. Addictive Behaviors, 2013, 38, 2325-2332.	3.0	44
16	Substance Use and High Risk Sexual Behaviors among Women in Psychosocial Outpatient and Methadone Maintenance Treatment Programs. American Journal of Drug and Alcohol Abuse, 2009, 35, 368-374.	2.1	43
17	Relationship Power and Sexual Risk among Women in Community-Based Substance Abuse Treatment. Journal of Urban Health, 2009, 86, 951-964.	3.6	41
18	Baseline Matters: The Importance of Covariation for Baseline Severity in the Analysis of Clinical Trials. American Journal of Drug and Alcohol Abuse, 2011, 37, 446-452.	2.1	41

#	Article	IF	CITATIONS
19	Attendance and substance use outcomes for the Seeking Safety program: Sometimes less is more Journal of Consulting and Clinical Psychology, 2012, 80, 29-42.	2.0	40
20	Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse. Journal of Substance Abuse Treatment, 2015, 48, 8-12.	2.8	40
21	Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. American Journal on Addictions, 2018, 27, 465-470.	1.4	40
22	Adverse events in an integrated trauma-focused intervention for women in community substance abuse treatment. Journal of Substance Abuse Treatment, 2008, 35, 304-311.	2.8	39
23	The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment, 2020, 112, 4-11.	2.8	39
24	How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies. Addiction, 2019, 114, 708-718.	3.3	38
25	Acceptability of a Web-Based Community Reinforcement Approach for Substance Use Disorders with Treatment-Seeking American Indians/Alaska Natives. Community Mental Health Journal, 2015, 51, 393-403.	2.0	36
26	Helping Alliance, Retention, and Treatment Outcomes: A Secondary Analysis From the NIDA Clinical Trials Network Women and Trauma Study. Substance Use and Misuse, 2012, 47, 695-707.	1.4	33
27	Opioid Use Disorder in Women and the Implications for Treatment. Psychiatric Research and Clinical Practice, 2021, 3, 3-11.	2.4	33
28	Indirect effects of 12â€session seeking safety on substance use outcomes: Overall and attendance classâ€specific effects. American Journal on Addictions, 2014, 23, 218-225.	1.4	31
29	Technology-Based Interventions for Substance Use and Comorbid Disorders: An Examination of the Emerging Literature. Harvard Review of Psychiatry, 2017, 25, 123-134.	2.1	30
30	Retention in the National Institute on Drug Abuse Clinical Trials Network Women and Trauma Study: Implications for posttrial implementation American Journal of Orthopsychiatry, 2011, 81, 211-217.	1.5	29
31	Using digital technologies in clinical trials: Current and future applications. Contemporary Clinical Trials, 2021, 100, 106219.	1.8	28
32	Differences between Men and Women in Condom Use, Attitudes, and Skills in Substance Abuse Treatment Seekers. American Journal on Addictions, 2013, 22, 150-157.	1.4	27
33	The Increasing Prevalence of Fentanyl: A Urinalysisâ€Based Study Among Individuals With Opioid Use Disorder in New York City. American Journal on Addictions, 2021, 30, 65-71.	1.4	26
34	Substance Use Disorders and HIV/AIDS Prevention and Treatment Intervention: Research and Practice Considerations. Social Work in Public Health, 2013, 28, 333-348.	1.4	24
35	Consistent Estimates of Very Low HIV Incidence Among People Who Inject Drugs: New York City, 2005–2014. American Journal of Public Health, 2016, 106, 503-508.	2.7	23
36	Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis. Journal of Substance Abuse Treatment, 2019, 97, 41-46.	2.8	22

#	Article	IF	CITATIONS
37	Model and approach for assessing implementation context and fidelity in the HEALing Communities Study. Drug and Alcohol Dependence, 2020, 217, 108330.	3.2	22
38	Racial/Ethnic Match and Treatment Outcomes for Women with PTSD and Substance Use Disorders Receiving Community-Based Treatment. Community Mental Health Journal, 2014, 50, 811-822.	2.0	21
39	Exploring the relationship between eating disorder symptoms and substance use severity in women with comorbid PTSD and substance use disorders. American Journal of Drug and Alcohol Abuse, 2015, 41, 547-52.	2.1	21
40	Web-based treatment for substance use disorders: Differential effects by primary substance. Addictive Behaviors, 2015, 45, 191-194.	3.0	20
41	Substance Use, Childhood Sexual Abuse, and Sexual Risk Behavior among Women in Methadone Treatment. American Journal of Drug and Alcohol Abuse, 2009, 35, 305-310.	2.1	19
42	Predictors of Relationship Power Among Drug-Involved Women. AIDS and Behavior, 2012, 16, 1532-1541.	2.7	19
43	Synergy between Seeking Safety and Twelve-Step Affiliation on substance use outcomes for women. Journal of Substance Abuse Treatment, 2013, 45, 179-189.	2.8	19
44	Cigarette Smoking During Substance Use Disorder Treatment: Secondary Outcomes from a National Drug Abuse Treatment Clinical Trials Network study. Journal of Substance Abuse Treatment, 2015, 53, 39-46.	2.8	19
45	Associations between Postâ€Traumatic Stress Symptoms, Stimulant Use, and Treatment Outcomes: A Secondary Analysis of NIDA's Women and Trauma Study. American Journal on Addictions, 2014, 23, 90-95.	1.4	18
46	Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. American Journal of Psychiatry, 2021, 178, 660-671.	7.2	18
47	Quality assurance of research protocols conducted in the community: The National Institute on Drug Abuse Clinical Trials Network Experience. Clinical Trials, 2009, 6, 151-161.	1.6	17
48	Changes in Sleep Disruption in the Treatment of Coâ€Occurring Posttraumatic Stress Disorder and Substance Use Disorders. Journal of Traumatic Stress, 2014, 27, 82-89.	1.8	17
49	Female Condom Skill and Attitude: Results from a NIDA Clinical Trials Network Gender-Specific HIV Risk Reduction Study. AIDS Education and Prevention, 2011, 23, 329-340.	1.1	16
50	Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study. International Journal of Drug Policy, 2020, 79, 102751.	3.3	15
51	Workshop on Implementation Science and Digital Therapeutics for Behavioral Health. JMIR Mental Health, 2021, 8, e17662.	3.3	15
52	Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone. Drug and Alcohol Dependence, 2019, 205, 107649.	3.2	14
53	Using community engagement to implement evidence-based practices for opioid use disorder: A data-driven paradigm & systems science approach. Drug and Alcohol Dependence, 2021, 222, 108675.	3.2	14
54	Characteristics of an Outpatient Treatment Sample by Primary Substance of Abuse. Journal of Addiction Medicine, 2013, 7, 363-371.	2.6	13

#	Article	IF	CITATIONS
55	Contingency Management Abstinence Incentives: Cost and Implications for Treatment Tailoring. Journal of Substance Abuse Treatment, 2017, 72, 134-139.	2.8	13
56	Perspectives on trauma and the design of a technology-based trauma-informed intervention for women receiving medications for addiction treatment in community-based settings. Journal of Substance Abuse Treatment, 2020, 112, 92-101.	2.8	13
57	The "Women and Trauma―study and its national impact on advancing trauma specific approaches in community substance use treatment and research. Journal of Substance Abuse Treatment, 2020, 112, 12-17.	2.8	13
58	Maximizing Effectiveness Trials in PTSD and SUD Through Secondary Analysis: Benefits and Limitations Using the National Institute on Drug Abuse Clinical Trials Network "Women and Trauma" Study as a Case Example. Journal of Substance Abuse Treatment, 2015, 56, 23-33.	2.8	12
59	Changing Trends in Substance Use and Sexual Risk Disparities among Sexual Minority Women as a Function of Sexual Identity, Behavior, and Attraction: Findings from the National Survey of Family Growth, 2002–2015. Archives of Sexual Behavior, 2019, 48, 1137-1158.	1.9	12
60	Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. Journal of Substance Abuse Treatment, 2021, 131, 108447.	2.8	12
61	Depressive Symptoms and Associated Clinical Characteristics in Outpatients Seeking Community-Based Treatment for Alcohol and Drug Problems. Substance Abuse, 2015, 36, 297-303.	2.3	11
62	Providing ART to HIV Seropositive Persons Who Use Drugs: Progress in New York City, Prospects for "Ending the Epidemic― AIDS and Behavior, 2016, 20, 353-362.	2.7	11
63	Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addictive Behaviors, 2017, 65, 74-80.	3.0	11
64	Factor structure and psychometric properties of the Connor–Davidson resilience scale (CD-RISC) in individuals with opioid use disorder. Drug and Alcohol Dependence, 2021, 221, 108632.	3.2	11
65	Barriers to condom use: Results for men and women enrolled in HIV risk reduction trials in outpatient drug treatment. Journal of HIV/AIDS and Social Services, 2016, 15, 130-146.	0.7	10
66	"lt's Never Just About the HIV:―HIV Primary Care Providers' Perception of Substance Use in the Era of "Universal―Antiretroviral Medication Treatment. AIDS and Behavior, 2018, 22, 1006-1017.	2.7	10
67	Factors Influencing Buprenorphine Prescribing among Physicians in New York State. Journal of Addiction, 2019, 2019, 1-5.	0.9	10
68	Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis. Journal of Substance Abuse Treatment, 2020, 117, 108099.	2.8	10
69	HIV Treatment Knowledge in the Context of "Treatment as Prevention―(TasP). AIDS and Behavior, 2020, 24, 2984-2994.	2.7	10
70	Racial/ethnic subgroup differences in outcomes and acceptability of an Internet-delivered intervention for substance use disorders. Journal of Ethnicity in Substance Abuse, 2017, 16, 460-478.	0.9	10
71	What happened to the HIV epidemic among nonâ€injecting drug users in New York City?. Addiction, 2017, 112, 290-298.	3.3	9
72	Racial/Ethnic Disparities at the End of an HIV Epidemic: Persons Who Inject Drugs in New York City, 2011–2015. American Journal of Public Health, 2017, 107, 1157-1163.	2.7	9

#	Article	IF	CITATIONS
73	Addiction Research Training Programs: Four Case Studies and Recommendations for Evaluation. Journal of Addiction Medicine, 2017, 11, 333-338.	2.6	9
74	Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001–2005 and 2011–2015. Drug and Alcohol Dependence, 2018, 185, 391-397.	3.2	9
75	Cognitive functioning and treatment outcomes in a randomized controlled trial of internetâ€delivered drug and alcohol treatment. American Journal on Addictions, 2018, 27, 509-515.	1.4	9
76	Place-based predictors of HIV viral suppression and durable suppression among heterosexuals in NewÂYork city. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 864-874.	1.2	9
77	Methodological innovation to increase the utility and efficiency of psychotherapy research for patients with co-occurring mental health and substance use disorders Professional Psychology: Research and Practice, 2009, 40, 502-509.	1.0	8
78	ls Monogamy or Committed Relationship Status a Marker for Low Sexual Risk among Men in Substance Abuse Treatment? Clinical and Methodological Considerations. American Journal of Drug and Alcohol Abuse, 2011, 37, 294-300.	2.1	8
79	From Long-Term Injecting to Long-Term Non-Injecting Heroin and Cocaine Use: The Persistence of Changed Drug Habits. Journal of Substance Abuse Treatment, 2016, 71, 48-53.	2.8	8
80	Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use Disorders. Journal of Addiction Medicine, 2018, 12, 99-106.	2.6	8
81	Posttraumatic stress symptoms, shame, and substance use among Asian Americans. Journal of Substance Abuse Treatment, 2019, 96, 1-11.	2.8	8
82	Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder. Substance Abuse, 2020, 42, 1-5.	2.3	8
83	Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder. Journal of Addiction Medicine, 2020, 14, e188-e194.	2.6	8
84	Marketing Effectiveness in Reaching the Nontreatment-Seeking Marijuana Smoker. Journal of Social Work Practice in the Addictions, 2004, 4, 39-59.	0.7	7
85	Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. Journal of Substance Abuse Treatment, 2021, 124, 108292.	2.8	7
86	Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes. Journal of Substance Abuse Treatment, 2022, 132, 108585.	2.8	7
87	Toward National Estimates of Effectiveness of Treatment for Substance Use. Journal of Clinical Psychiatry, 2017, 78, e64-e70.	2.2	7
88	Gender Differences in Heterosexual Anal Sex Practices Among Women and Men in Substance Abuse Treatment. AIDS and Behavior, 2013, 17, 2450-2458.	2.7	6
89	Demographic and Clinical Characteristics of Middle-aged Versus Younger Adults Enrolled in a Clinical Trial of a Web-delivered Psychosocial Treatment for Substance Use Disorders. Journal of Addiction Medicine, 2013, 7, 66-72.	2.6	6
90	Strength in the midst of pain: Abuse as a predictor of sexual relationship power among substance-abusing Black women. Journal of Ethnicity in Substance Abuse, 2017, 16, 432-444.	0.9	6

#	Article	IF	CITATIONS
91	Place-Based Predictors of HIV Viral Suppression and Durable Suppression Among Men Who Have Sex With Men in New York City. AIDS and Behavior, 2017, 21, 2987-2999.	2.7	6
92	DSM-5 substance use disorder symptom clusters and HIV antiretroviral therapy (ART) adherence. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 645-650.	1.2	6
93	Men in Methadone Maintenance versus Psychosocial Outpatient Treatment: Differences in Sexual Risk Behaviors and Intervention Effectiveness from a Multisite HIV Prevention Intervention Trial. Journal of Addictive Diseases, 2010, 29, 370-382.	1.3	5
94	NIDA's Clinical Trials Network: An Opportunity for HIV Research in Community Substance Abuse Treatment Programs. American Journal of Drug and Alcohol Abuse, 2011, 37, 283-293.	2.1	5
95	Community Providers' Impression of Hiv Prevention Intervention Research in Nida's Clinical Trials Network. Journal of Drug Issues, 2011, 41, 441-459.	1.2	5
96	Transdisciplinary collaboration and endorsement of pharmacological and psychosocial evidence-based practices by medical and psychosocial substance abuse treatment providers in the United States. Drugs: Education, Prevention and Policy, 2013, 20, 408-416.	1.3	5
97	Antiretroviral medication treatment for all HIV-infected individuals: a protocol using innovative multilevel methodologies to evaluate New York City's universal ART policy among problem substance users. BMC Health Services Research, 2016, 16, 341.	2.2	5
98	Sociodemographic and Substance Use Disorder Determinants of HIV Sexual Risk Behavior in Men and Women in Outpatient Drug Treatment in the NIDA National Drug Abuse Treatment Clinical Trials Network. Substance Use and Misuse, 2017, 52, 858-865.	1.4	5
99	Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults. Addictive Behaviors, 2020, 110, 106514.	3.0	5
100	A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City International Journal of Drug Policy, 2021, 87, 102968.	3.3	5
101	COVID-19 related substance use services policy changes: Policymaker perspectives on policy development & implementation. Journal of Substance Abuse Treatment, 2021, , 108550.	2.8	5
102	Durable Viral Suppression Among People with HIV and Problem Substance Use in the Era of Universal Antiretroviral Treatment. AIDS and Behavior, 2022, 26, 385-396.	2.7	5
103	Substance Use and Mental Health in Emerging Adult Vs Older Adult Men and Women With Opioid Use Disorder. American Journal on Addictions, 2020, 29, 536-542.	1.4	5
104	Safety and Efficacy of a Digital Therapeutic for Substance use Disorder: Secondary Analysis of Data from a NIDA Clinical Trials Network Study. Substance Abuse, 2022, 43, 937-942.	2.3	5
105	A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder. Drug and Alcohol Dependence, 2022, 237, 109505.	3.2	5
106	Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables. Addiction, 2021, 116, 2094-2103.	3.3	4
107	Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. American Journal on Addictions, 2021, 30, 433-444.	1.4	4
108	Web-based, psychosocial treatment for substance use disorders in community treatment settings Psychological Services, 2012, 9, 212-214.	1.5	3

#	Article	IF	CITATIONS
109	Exploring gender differences among treatment-seekers who use opioids versus alcohol and other drugs. Women and Health, 2020, 60, 821-838.	1.0	3
110	Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment, 2021, 130, 108489.	2.8	3
111	Is extended release naltrexone superior to buprenorphineâ€naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Alcoholism: Clinical and Experimental Research, 2021, 45, 2569-2578.	2.4	3
112	Patient Engagement With a Game-Based Digital Therapeutic for the Treatment of Opioid Use Disorder: Protocol for a Randomized Controlled Open-Label, Decentralized Trial. JMIR Research Protocols, 2022, 11, e32759.	1.0	3
113	Heterosexual Anal Sex Among Men and Women in Substance Abuse Treatment: Secondary Analysis of Two Gender-Specific HIV-Prevention Trials. Journal of Sex Research, 2017, 54, 33-41.	2.5	2
114	Decline in Herpes Simplex Virus Type 2 Among Non-Injecting Heroin and Cocaine Users in New York City, 2005 to 2014: Prospects for Avoiding a Resurgence of Human Immunodeficiency Virus. Sexually Transmitted Diseases, 2017, 44, 85-90.	1.7	2
115	Psychological Symptoms and Outcomes in Adults Receiving Community-based Treatment for Substance Use Disorders. Substance Use and Misuse, 2021, 56, 1258-1265.	1.4	2
116	Recommendations to Inform Substance Use Disorder Data Sharing Research: Scoping Review and Thematic Analysis. Journal of Addiction Medicine, 2022, 16, 261-271.	2.6	2
117	Emotional Reactions of Trained Overdose Responders who use Opioids following Intervention in an Overdose Event. Substance Abuse, 2022, 43, 581-591.	2.3	2
118	Comparison of 2 Measures of HIV Sexual Risk Behavior in Women in Outpatient Drug Treatment Programs. Journal of Addiction Medicine, 2015, 9, 454-456.	2.6	1
119	Will "Combined Prevention" Eliminate Racial/Ethnic Disparities in HIV Infection among Persons Who Inject Drugs in New York City?. PLoS ONE, 2015, 10, e0126180.	2.5	1
120	Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders. Journal of Substance Abuse Treatment, 2019, 105, 64-70.	2.8	1
121	Depression and Suicidal Ideation in Adults With Opioid Use Disorder Treated With Buprenorphine-Naloxone Versus Extended-Release Naltrexone. Biological Psychiatry, 2020, 87, S268-S269.	1.3	1
122	Multi-informant Implementation and Intervention Outcomes of Opioid Overdose Education and Naloxone Distribution in New York City. Global Implementation Research and Applications, 2021, 1, 209-222.	1.1	1
123	Responding to the Opioid Crisis: Lessons From a Review of Casualties. Psychiatric Services, 2019, 70, 89-89.	2.0	0
124	Sexual Risk Among African Americans in Substance Use Treatment: Secondary Analysis of Two Clinical Trials. Sexuality and Culture, 2020, 24, 2065-2078.	1.5	0
125	Understanding preferences for type of take-home naloxone device: international qualitative analysis of the views of people who use opioids. Drugs: Education, Prevention and Policy, 0, , 1-12.	1.3	0
126	Support for COVID-19-Related Substance Use Services Policy Changes: a New York State-Wide Survey. Journal of Behavioral Health Services and Research, 2022, , 1.	1.4	0